GlassScriptPhysician profile
Randy A Lieberman
NPI 1679513543
$1,184,124.36
in general payments reported to CMS, 2019-2025
33 companies · $33K in 2025
The $33K reported for 2025 was more than what 93% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173K · 2020: $219K · 2021: $244K · 2022: $273K · 2023: $158K · 2024: $84K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $234K · Travel and Lodging: $13K · Food and Beverage: $9,526 · Consulting Fee: $9,486 · Honoraria: $9,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $234,104.69 |
| Travel and Lodging | $12,943.35 |
| Food and Beverage | $9,525.98 |
| Consulting Fee | $9,486.00 |
| Honoraria | $9,190.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $384,335.59 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $373,944.29 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $100,233.35 | 2020-2024 | Jardiance |
| Amgen INC. | $80,034.12 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $51,881.67 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $49,829.84 | 2021-2024 | Verquvo |
| Pfizer INC. | $45,730.77 | 2019-2025 | |
| Lilly USA, LLC | $29,022.24 | 2021-2024 | Jardiance |
| Novo Nordisk INC | $25,075.15 | 2024-2025 | Wegovy |
| Elutia, INC. | $15,193.68 | 2019-2023 | |
| Medtronic, INC. | $14,134.89 | 2021-2025 | Linq II, Micra, Cobalt Dr Mri Surescan |
| Itamar Medical INC | $3,817.79 | 2023-2024 | Watchpatone |
| Medtronic Vascular, INC. | $2,982.71 | 2019-2020 | |
| Abbott Laboratories | $2,071.07 | 2022-2025 | Aveir, Cardiomems |
| Impulse Dynamics (USA) INC. | $1,503.77 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Altathera Pharmaceuticals LLC | $1,125.00 | 2024 | Sotalol Hydrochloride |
| Kestra Medical Technology Services, INC. | $611.15 | 2024-2025 | Assure Wcd |
| Boston Scientific Corporation | $605.12 | 2023-2025 | Emblem Mri S-Icd, Empower Leadless Pacemaker System_crm, Lux-Dx Insertable Cardiac Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $574.98 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $514.71 | 2019-2025 | Eliquis |
| Alnylam Pharmaceuticals INC. | $286.43 | 2024-2025 | Amvuttra |
| Zoll Respicardia, INC. | $148.82 | 2019 | |
| Medtronic USA, INC. | $136.60 | 2019 | |
| Cordis US Corp. | $79.74 | 2025 | Mynx Control Venous, Mynxgrip |
| Novartis Pharmaceuticals Corporation | $77.20 | 2020-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $37.06 | 2022 | |
| Sobi, INC | $36.76 | 2021 | |
| Edwards Lifesciences Corporation | $34.24 | 2024 | Pascal |
| Cleerly, INC. | $34.10 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Dynavax Technologies Corporation | $14.80 | 2022 | |
| Cardiofocus, INC. | $12.50 | 2022 | |
| Janssen Scientific Affairs, LLC | $4.22 | 2024 | Xarelto |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randy Lieberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.